|
NCI Launches Network to Study Self-Collection for HPV Testing to Prevent Cervical Cancer
On January 25, 2024, the National Cancer Institute (NCI), part of the National Institutes of Health, with public and private partners, launched a new clinical trial network to gather data on a “self-collection” method of human papillomavirus (HPV) testing to prevent cervical cancer.
Read the Cancer Prevention Science Blog.
|
Research Highlights: Barrett’s Esophagus Translational Research Network Studies Provide Insights into Prevention and Risk for Esophageal Cancer
What Happens If More People Get Screened for Cancer?
2024 Annual Call for Nominations to Spotlight Early Career Scientists
Nominations are now open to spotlight your early career scientists in cancer prevention, early detection biomarker development and screening, and symptom science. NCI wants to increase visibility of and provide recognition to the early career scientists conducting research within the areas supported by the Division of Cancer Prevention (DCP). Please nominate an early career scientist you believe should be recognized for their hard work. Individuals who are selected will be featured on social media and will be invited to present their research to the broad NCI community. Applications are due June 30.
Learn more about this opportunity.
|
|
DCP Early Career Scientist Spotlight Research Seminar Series
20th Virtual National Cancer Advisory Board Meeting
Thursday, February 8 10:00 a.m.-4:15 p.m. ET Watch Live Videocast
Mark your calendars for the 20th Virtual Meeting of the National Cancer Advisory Board (view tentative agenda). This virtual meeting is open to the public and will be broadcast live at videocast.nih.gov. To view the videocast, you must have Adobe Flash Player installed.
|
|
|
Notice of Funding Opportunities (NOFOs): Assay Validation for Studies in Cancer |
|
Assay Validation of High-Quality Markers for Clinical Studies in Cancer
NCI invites applications to support the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO supports investigator-initiated research for both analytical and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by NCI.
PAR-23-313 (UH2/UH3 Clinical Trial Not Allowed) PAR-23-314 (UH3 Clinical Trials Not Allowed)
Expires: October 15, 2026
|
|
|
|